Flerie Invest AB entered into an agreement to acquire InDex Pharmaceuticals Holding AB (publ) in a reverse merger transaction on May 20, 2024. As a part of consideration 6,073,952,948 new shares wil be issued. Flerie's shareholders will initially hold approximately 91.9 per cent of the total number of shares and votes in the InDex Pharmaceuticals. As a result of the Transaction, the Company will change its name to Flerie AB. The transaction is subject to InDex Pharmaceuticals shareholders approval. The completion of the Transaction is, among other things, conditional upon resolutions at the EGMs and that the Company receives approval for continued listing on Nasdaq First North Growth Market. As on June 7, 2024, InDex Pharmaceuticals has today received a conditional approval from Nasdaq Stockholm for continued listing of the Company's share on Nasdaq First North Growth Market. The Company has previously submitted an application for approval for continued listing as a part of the completion of the reverse merger of Flerie Invest AB.

Redeye AB acted as financial advisor to InDex Pharmaceuticals Holding AB. Setterwalls Advokatbyrå Ab acted as legal advisor to InDex Pharmaceuticals Holding AB. KANTER Advokatbyrå KB acted as legal advisor to Flerie Invest AB.